The European Medicines Agency's committee has recommended approval of French drugmaker Sanofi's first-of-its-kind drug that ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...

Regulators upheld their earlier decision after reexamination, saying the substance does not meet the criteria for new active ...

Shortly after crossing the FDA’s finish line, Ionis Pharmaceuticals’ RNA-targeted hereditary angioedema (HAE) treatment ...

Fondazione Telethon announces the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the ...

Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license ...

Scholar Rock soared by 24.41 percent on Friday to close at $37.41 apiece as investor sentiment was boosted by the progress of ...

In the evolving Indian health care ecosystem, ease of doing business is no longer just an economic reform — it’s a health care reform. Streamlined regulations, harmonised standards, and transparent ...

Investing.com -- Ionis Pharmaceuticals Inc (NASDAQ:IONS) stock rose 3.1% on Friday following a positive regulatory development for its hereditary angioedema treatment in Europe.

Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue - - Reports positive feedback from the FDA ...

A forthcoming HSE assessment will determine who qualifies for Mounjaro, with access likely restricted to high-risk patients due to cost ...

Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.